Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Tongue Drive System Enables Quadriplegics To Operate Powered Wheelchair In Clinical Trial
An assistive technology that enables individuals to maneuver a powered wheelchair or control a mouse cursor using simple tongue movements can be operated by individuals with high-level spinal cord injuries, according to the results of a recently completed clinical trial.
generic viagra online
House Democrats May Skip Committee Vote, Take Bill To Floor
"House Democrats spent another day Thursday negotiating their health reform overhaul with few concrete signs of progress, heightening tensions and raising the possibility that leaders might bypass the House Energy and Commerce Committee and send the bill straight to the floor," CongressDailyAM reports. "The seven Blue Dog Coalition members on the panel emerged from a three-hour meeting with leaders and White House officials Thursday afternoon with little to say" (Hunt and House, 7/24).
News of the day
DRSI Launches The First And Only Diabetes Energy Formula Specifically Created For Diabetics To Counter Their No. 1 Complaint: Fatigue
Diabetica Research Solutions, Inc. (DRSI) http://www.drsirestoreenergy.com: Diabetes is a disease of energy currently affecting 24 million people who have been diagnosed and approximately 55 million who are in a pre-diabetic condition. For so many of these people with diabetes, particularly those with type 2 diabetes, persistent fatigue is a constant complaint. According to a 2007 survey of 8,000 people with diabetes, approximately 85% of respondents reported that fatigue was their number one complaint. When asked how they dealt with their fatigue, 17% of respondents said they do nothing, 31% drink water, 23% drink coffee, 6% drink energy drinks and 23% drink sodas and diet sodas. Now, with the introduction of drsi™ Restore! Energy, there"s a quick and effective way for diabetics and pre-diabetics to experience balanced, long lasting energy and stamina to help them through their daily routines.
Oncology

Strativa's New Drug Application For Ondansetron Orally Dissolving Film Strip Accepted By FDA

Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for ondansetron orally dissolving film strip (ODFS). Strativa is seeking approval of ondansetron ODFS for the prevention of nausea and vomiting associated with highly- and moderately-emetogenic chemotherapy, radiotherapy and surgery. The ODFS, a new oral formulation of ondansetron designed to rapidly dissolve on the tongue, was developed using MonoSol Rx" proprietary PharmaFilm(TM) thin film technology. In clinical studies, this formulation demonstrated bioequivalence to ondansetron orally disintegrating tablets (ODT), both with and without water. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, Strativa expects the FDA will complete its review or otherwise respond to the NDA by the first quarter of 2010. "We are very pleased with the acceptance of our NDA submission and look forward to cooperating with the FDA on its review," said John A. MacPhee, President, Strativa Pharmaceuticals. "We believe the quick dissolving film strip formulation of ondansetron offers a convenient and easy-to-administer option for managing nausea and vomiting associated with chemotherapy, radiotherapy and surgery." Nausea and vomiting is a common side effect associated with chemotherapy, radiation and surgery. Left untreated, nausea and vomiting can have serious consequences such as exhaustion, dehydration and undernourishment, which can interfere with treatment and healing. In June 2008, Strativa and MonoSol Rx entered into an exclusive licensing agreement under which Strativa acquired the U.S. commercialization rights to ondansetron orally dissolving film strip. About Strativa Pharmaceuticals Strativa Pharmaceuticals is the proprietary products division of Par Pharmaceutical, Inc. Strativa is committed to developing and marketing novel prescription drugs. Its initial focus is on supportive care therapeutics in HIV and oncology. Drawing on the specialty products expertise of its staff, Strativa possesses the res to prepare products for commercialization and to help ensure their success after launch. About Par Pharmaceutical Par Pharmaceutical, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. Safe Harbor Statement Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company"s Annual Report on Form 10-K for the year ended December 31, 2008, in other of the Company"s filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements. Par Pharmaceutical Companies, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009